SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending after securing a non-exclusive licensing agreement with Pfizer for its Matrix-M adjuvant, a deal seen by many as a significant validation of its platform technology across potential new disease areas. The community is actively discussing the potential for upfront payments, substantial milestones, and royalties, while also looking for further partnerships, particularly for its advanced COVID-Flu combination vaccine. This recent strategic move, alongside the company's strengthened financial position, is generating optimism about future growth despite ongoing activist investor pressure.

ProShares Trust - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

BOIL is currently experiencing a significant surge, fueled by an intense Arctic air invasion across the United States that is driving up natural gas demand and futures prices. The strong upward momentum has triggered a notable short squeeze, with the community actively discussing substantial profits and anticipating continued upside as extreme cold weather is projected to persist. This volatility is characteristic of the 2x leveraged ETF, attracting both profit-takers and those eyeing further gains.

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPDR S&P 500 ETF Trust is seeing heightened volatility as President Trump's escalating tariff threats against NATO allies, particularly concerning Greenland, spark widespread geopolitical uncertainty. Community sentiment is sharply divided, with some anticipating a deeper market correction while others view the current downturn as a 'buy the dip' opportunity amidst global bond market concerns and a notable rise in precious metal prices. Investors are closely monitoring a potential Supreme Court ruling on tariffs as a key market mover.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending ahead of its upcoming earnings, with community focus on its recent all-cash bid for Warner Bros. Discovery assets and a prominent figure's bond purchases. Bulls anticipate a significant rebound for the perceived oversold stock, highlighting its "tariff-proof" nature amidst a broader red market. Bears, however, warn of further downside, viewing the deal as a potential drag and suggesting market volatility around the report.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is trending due to overwhelmingly positive data from its Phase 1 clinical trial of soquelitinib for atopic dermatitis, with community discussions highlighting its strong efficacy in treatment-resistant patients. Investors are actively debating the potential for this novel oral ITK inhibitor to disrupt the significant atopic dermatitis market, fueling speculation of future partnerships or an acquisition and validating its broader immune-modulating platform.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is driving significant conversation as escalating US-EU trade tensions, particularly over Greenland and proposed tariffs, spark widespread market uncertainty and a risk-off shift. The community is sharply divided, with intense debate over whether current volatility signals a deeper correction or presents a key buying opportunity amidst ongoing institutional interest and broader macroeconomic shifts.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

Applovin ($APP) is experiencing significant volatility and a notable price decline following a new short report alleging the company's involvement in money laundering. This report has sparked intense debate among investors, with many attributing the drop to market manipulation and viewing it as a buying opportunity, while others express concern over the serious accusations despite recent bullish analyst upgrades.

BlackRock Institutional Trust Company N.A. - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

TLT is experiencing significant volatility amid escalating geopolitical tensions, notably the US asserting control over Venezuela's oil and ongoing debates surrounding US tariffs, fueling a "flight to quality" narrative for some. The community is actively discussing whether these events, alongside large institutional bond purchases, will continue to boost Treasuries as a safe haven or intensify concerns over US debt and the Federal Reserve's independence.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is generating significant buzz following positive regulatory advancements for its ANKTIVA therapy, with the FDA outlining a path to resubmission for papillary bladder cancer that requires no new clinical trials. This news, combined with recent international approvals, is fueling strong community sentiment around the potential for a "cancer cure" and intense discussions anticipating a substantial short squeeze.

ProShares Trust - ProShares UltraShort Bloomberg Natural Gas -2x Shares

ProShares UltraShort Bloomberg Natural Gas

KOLD is trending as natural gas prices sharply reverse, primarily driven by dramatically warmer weather forecasts that are erasing previous cold-snap gains. The community is actively discussing the extreme volatility and "widow maker" nature of natural gas ETFs, with many attempting to capitalize on KOLD's rapid ascent amidst widespread price uncertainty. This significant shift in winter weather expectations is compelling traders to adjust positions, leading to rapid price movements in inverse natural gas products.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Alumis (NASDAQ:ALMS) Stock Price Up 6.6% Following Insider Buying Activity

Alumis (NASDAQ:ALMS) Stock Price Up 6.6% Following Insider Buying Activity...

Wednesday 1/14 Insider Buying Report: ALMS, SPT

As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money. So let's look at two noteworthy recent insider buys. On...

Insider Buying: Alumis (NASDAQ:ALMS) Director Acquires 411,764 Shares of Stock

Alumis Inc. (NASDAQ:ALMS - Get Free Report) Director James Tananbaum purchased 411,764 shares of the company's stock in a transaction dated Thursday, January 8th. The stock was purchased at an...

Alumis (NASDAQ:ALMS) Major Shareholder Buys $6,999,988.00 in Stock

Alumis Inc. (NASDAQ:ALMS - Get Free Report) major shareholder Foresite Capital Management Vi bought 411,764 shares of the stock in a transaction on Thursday, January 8th. The shares were acquired at...

What's Going On With Alumis Stock Thursday?

Alumis Inc. is drawing attention with a major share sale and bullish analyst forecasts. The firm aims to fund its immune disease pipeline.read more...

<ul class="summary-bullets"><li>Investors turned cautious ahead of key U.S. jobs data and a potential court ruling on President Donald Trump’s global tariffs expected Friday.&nbsp;</li><li>Retail traders, however, stayed bullish on SPY and QQQ on Stocktwits.</li></ul>U.S. stock futures were lower early Thursday, following a pullback in major indexes. President&nbsp;Donald Trump’s policy comments triggered a late selloff, with defense, financial, and energy stocks under pressure.Investors are also cautious ahead of the big jobs data and the potential US court&nbsp;ruling on Trump’s global tariffs due on Friday.&nbsp;As of 3:00 a.m. ET on Thursday, Nasdaq 100 futures were down 0.3%, S&amp;P 500 futures and Dow futures were down 0.2%, while Russell 2000 futures fell 0.4%.On Stocktwits, however, retail sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF (SPY)</a>, an exchange-traded fund that tracks the S&amp;P 500 Index, remained ‘bullish’. While sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a> ETF, which tracks the Nasdaq 100 Index, has moved back to ‘bullish’ from ‘extremely bullish’ a day ago, amid high message volumes.<h2 class="st-heading-2">Trending Stocks To Watch</h2>Nvidia (NVDA): The Jensen Huang-led chipmaker is reportedly requiring full upfront payment, with&nbsp;no cancellation rights, for H200 chips from Chinese clients to hedge against regulatory export uncertainty. Microsoft (MSFT): The company’s communications&nbsp;chief took to social media to <a href="https://stocktwits.com/news-articles/markets/equity/microsoft-stock-in-focus-as-fresh-layoff-rumors-swirl/cmUGzFNR4PB">blast rumors</a> of fresh mass layoffs as "100% made up," attempting to steady the stock ahead of the&nbsp;market open. Apple (AAPL):&nbsp;Google parent Alphabet (GOOGL) surpassed Apple in market cap for the first time since 2019, closing at $3.888 trillion on Wednesday. It has also switched its banking partner from Goldman Sachs to JPMorgan, the new issuer of the Apple Card.&nbsp; Nio (NIO):&nbsp;The EV maker announced aggressive 2026 expansion plans for Australia, New Zealand, and Thailand, focusing on right-hand-drive markets to bypass Western tariffs. Applied Digital (APLD)&nbsp;saw a high volume of trading following its massive revenue growth report. Ventyx Biosciences (VTYX):&nbsp;Clear Street analyst downgraded the stock to ‘Hold’ from ‘Buy’ with a price target of $14, up from $11, after Eli Lilly (LLY) agreed to acquire Ventyx for $1.2B. Also, LifeSci Capital downgraded it to ‘Market Perform’ from ‘Outperform’ with a $14 price target.&nbsp; Alumis (ALMS) remains on retail radar following a massive ‘follow-on’ financing move following its recent clinical success. Alumis priced an&nbsp;upsized public offering of 17.65 million shares at&nbsp;$17 per share, aiming to raise&nbsp;$300 million. Elevai Labs (ELAB) popped 8%, and&nbsp;Omeros (OMER) rose 5% in after-hours trading on Wednesday, with Omeros gaining steam following a positive FDA conference call on its drug Yartemlea. U.S. defence stocks will be in focus, driven by&nbsp;Trump’s comments to bump up the military budget.Other noteworthy tickers trending on Stocktwits at the time of writing were&nbsp;One Stop Systems (OSS), Paramount Skydance (PSKY), IREN Limited (IREN), Momentus (MNTS), and Regencell Bioscience (RGC).Other Catalysts To Watch On the economic front, investors are looking ahead to the release of Initial Jobless Claims (8:30 a.m. ET), which is a crucial indicator ahead of Friday’s big employment report. Traders will also be monitoring the U.S. Trade Deficit &amp; Productivity data (8:30 a.m. ET) and Consumer Credit data (3 p.m. ET) later today.&nbsp; And noteworthy names on the earnings calendar today include Tilray Brands (TLRY), TD Synnex (SNX),&nbsp;Commercial Metals Company (CMC), and&nbsp;Neogen Corporation (NEOG), among others.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com

Nasdaq, S&P 500 Futures Dip As Investors Brace For Jobs Data, Tariff Ruling: Why NVDA, MSFT, AAPL, APLD, NIO Are On Traders' Radar Today

Nvidia, Apple, Microsoft, and select biotech names dominated early market buzz.

Equity

Nvidia, Apple, Microsoft, and select biotech names dominated early market buzz.


ALMS Surges as Envudeucitinib Meets Goals in Plaque Psoriasis Studies

Alumis shares jump 95% after envudeucitinib meets all endpoints in two phase III plaque psoriasis studies, showing strong skin clearance.

<ul class="summary-bullets"><li>Fed’s Michelle Bowman is also set to speak later in the day.</li><li>On the earnings calendar, notable names reporting include Applied Digital (APLD), Constellation Brands (STZ), Albertsons (ACI), and Cal-Maine Foods (CALM).</li></ul>U.S. stock futures were little changed early Wednesday as investors positioned ahead of key economic data and Fed commentary. Traders are watching for the December ADP employment and ISM Services PMI data, both due later today.As of 3:40 a.m. ET on Wednesday, Nasdaq 100 futures were down 0.2%, S&amp;P 500 and Dow futures were flat, while Russell 2000 futures gained 0.1%.On Stocktwits, however, retail sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF (SPY)</a>, an exchange-traded fund that tracks the S&amp;P 500 Index, remained ‘bullish’. While sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a> ETF, which tracks the Nasdaq 100 Index, has flipped to ‘extremely bullish’ from ‘bullish’, amid high message volumes.Trending Stocks To Watch Nvidia (NVDA): CEO Jensen Huang has flagged ‘very high’ China demand for H200 chips and added that the company is working with the US government on final export license details. Meta (META): Chinese officials are reportedly reviewing Meta’s acquisition of Singapore-based AI firm Manus to assess whether the transfer of Chinese-origin AI tech required an export license. Applied Digital (APLD) is among the top-trending tickers on Stocktwits ahead of its earnings report today.&nbsp;Ventyx Biosciences (VTYX):&nbsp;Stock surged after hours following reports that Eli Lilly is nearing a $1B+ acquisition. A whole host of memory chip stocks, including SanDisk (SNDK), Western Digital (WDC), Micron (MU), and Seagate (STX), hit new highs amid&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sandisk-wdc-seagate-which-memory-stock-is-the-better-bet/cmxyrKqR4cK">concerns</a> over a critical shortage of memory-making machinery. Amazon (AMZN) is gaining retail attention amid reports that traders have pushed back against its AI shopping tool, alleging it scraped product data without consent.&nbsp; MobilEye Global (MBLY): Stock gained after-hours after agreeing to buy Mentee Robotics in a cash-and-stock deal.&nbsp; Oil stocks (CVX, EXOM) remain in focus President Trump announced interim Venezuelan authorities will transfer 30M–50M barrels of oil to the US, causing Brent crude to slide toward $57-$60/bbl. Alumis (ALMS) remains on retail radar following&nbsp;its Phase 3 psoriasis trial results, which prompted multiple analysts to&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/alumis-stock-hits-record-high-as-wall-street-cheers-phase-3-psoriasis-win-analysts-see-best-in-class-potential/cmxynYnR4cB">raise price targets</a> and reiterate bullish ratings on the stock. Other noteworthy tickers trending on Stocktwits at the time of writing were&nbsp;Terrestrial Energy (IMSR), Critical Metals Corp (CRML), and Regencell Bioscience (RGC). Other Catalysts To Watch On the economic front, investors are looking ahead to the release of December ADP employment figures, scheduled for 8:15 a.m. ET, setting the tone ahead of official payrolls. The ISM Services PMI data is due at 10:00 am ET.&nbsp; Fed Vice Chair for Supervision Michelle Bowman is scheduled to speak later in the day. And noteworthy names on the earnings calendar today include Applied Digital (APLD), Constellation Brands (STZ), Albertsons Companies (ACI), and Cal-Maine Foods (CALM), among others. For updates and corrections, email newsroom[at]stocktwits[dot]com

Nasdaq, S&P 500 Futures Tread Water Ahead Of ADP Data: Why NVDA, META, APLD, VTYX, ALMS Are On Traders' Radar Today

Nvidia, memory-chip stocks, and AI-linked names dominated chatter ahead of data and earnings.

<ul class="summary-bullets"><li>Analysts lifted price targets and reaffirmed bullish ratings after the Phase 3 results.</li><li>The new trial data showed strong skin clearance with results improving over time.</li><li>Alumis outlined plans for an FDA filing in 2026.</li></ul>Shares of Alumis Inc. hit a record high after Wall Street responded positively to the company’s Phase 3 psoriasis trial results, prompting multiple analysts to raise price targets and reiterate bullish ratings on the stock.The rally followed Alumis’ announcement of&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-is-alms-stock-rising-today/cmxwvW3R4Tk">positive topline data from its Phase 3 Onward program</a> evaluating Envudeucitinib in patients with moderate-to-severe plaque psoriasis.<a href="https://stocktwits.com/symbol/ALMS">Alumis’ stock</a> surged over 95% on Tuesday to $16.23, and added another 3% in after hours trading.&nbsp;<h2 class="st-heading-2">Leerink, Oppenheimer Raise Targets After Trial ‘Win’</h2>Following the data, Leerink Partners raised its price target on Alumis to $32 from $20 and maintained an ‘Outperform’ rating, implying upside of about 100% from the stock’s last close.The firm said the strong topline results and additional details from the investor call reinforced Envudeucitinib’s favorable clinical profile and reignited strategic optionality around what it described as a “potentially best-in-class” Tyrosine Kinase 2 (TYK2) franchise, calling the outcome a clear “win.”Separately, Oppenheimer raised its price target to $50 from $25 and reiterated an ‘Outperform’ rating, implying upside of about 212% from the stock’s last close. Analyst Jeff Jones said Envudeucitinib appears “highly competitive and potentially superior to Icotrokinra on some endpoints” following the trial results.<h2 class="st-heading-2">Phase 3 Data Shows High Levels Of Skin Clearance</h2>Alumis said Envudeucitinib met all primary and secondary endpoints in both Onward1 and Onward2 trials with high statistical significance. By 16 weeks, 74% of patients saw major improvement in their psoriasis, and nearly 60% had skin that was clear or almost clear across the two studies.By 24 weeks, Alumis said about two-thirds of patients saw near-complete clearing of their psoriasis, while more than 40% had completely clear skin. The company also said Envudeucitinib performed better than the standard treatment across all key measures of skin improvement at that point in the trial.The company said treatment was generally well tolerated through Week 24, with a safety profile consistent with its Phase 2 program and no new safety signals observed.<h2 class="st-heading-2">Regulatory Timeline</h2>Alumis said it plans to submit a New Drug Application to the U.S. Food and Drug Administration in the second half of 2026 and expects to present additional Onward data at an upcoming medical meeting.Envudeucitinib is also being tested as a potential treatment for lupus, another autoimmune disease, with topline data from the Phase 2b Lumus trial expected in the third quarter of 2026.After releasing the Phase 3 data, Alumis announced plans for an underwritten public offering of $175 million of common stock, with an option for underwriters to purchase additional shares.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for Alumis was ‘extremely bullish’ amid ‘extremely high’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/alms_ss_png_ddce06f504.webp" alt="alms ss.png" width="971" height="143"><figcaption>ALMS sentiment and message volume as of January 6| Source: Stocktwits</figcaption></figure>One user said the company has no debt, ample cash on hand, and a positive long-term outlook.<stembedurl>https://stocktwits.com/prohibited/message/641002483</stembedurl>Another user said they expect the stock to hold above $16 after the offering, move gradually toward the $18–$20 range, and then potentially pull back afterward.<stembedurl>https://stocktwits.com/Donniechen12345/message/641021469</stembedurl><a href="https://stocktwits.com/symbol/ALMS">Alumis’ stock</a> has risen 92% over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Alumis logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Alumis Stock Hits Record High As Wall Street Cheers Phase 3 Psoriasis ‘Win’ — Analysts See Best-In-Class Potential

The company also disclosed plans of a $175 million underwritten share offering after releasing its Phase 3 trial data.

Sandisk, Alumis, Micron Technology, Ventyx Biosciences, And Western Digital: Why These 5 Stocks Are On Investors' Radars Today

SNDK, ALMS, MU, VTYX, WDC were among the stocks seen trending among investors on Tuesday, Jan. 6, 2026.read more...

Alumis, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. It focuses on building a pipeline of molecules with the potential to address a broad range of immune-mediated diseases such as monotherapy or combination therapies. The company was founded on January 29, 2021 and is headquartered in San Francisco, CA.

Current Price	$23.86
Prev Close	$24.17
Open	$23.90
Dividend Yield	0.00%
50-Day Moving Average	$10.77
Beta	0.87
Avg. Volume	1.22M
PE Ratio	-6.19

52-Week High	$25.19
52-Week Low	$2.76
Market Capitalization	$2.98B
EPS (Annual)	-$5.41
Price to Book	6.47
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

ALMS
Alumis Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ALMS News

ALMSAlumis Inc.